Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 0
Sponsor overview
Klus Pharma .
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT03602079 | https://clinicaltrials.gov/study/NCT04152499 | https://clinicaltrials.gov/study/NCT05631262
Assets